New Treatment Strategy Makes Cancer Cells Run Out of Energy and Die (opens in a new tab)

In plain English

The authors used in silico molecular docking and medicinal chemistry-based structure-driven optimization to generate AcTor, described as a potential first-in-class small-molecule inhibitor of TSC2 intended to stimulate mTORC1.

Key findings

• Generation of AcTor via in silico docking and medicinal chemistry, described as a potential first-in-class small-molecule TSC2 inhibitor (mTOR stimulator).

In plain English

In ex vivo assays of primary patient-derived acute myeloid leukemia (AML) samples, the novel TSC2 inhibitor AcTor potentiated the cytotoxic activity of the proteasome inhibitor ixazomib (IXZ). The paper reports that this potentiation was observed across multiple AML cell lines and primary patient samples; combination treatment in the tested models is associated with mitochondrial respiratory collapse, loss of mitochondrial membrane potential, accumulation of reactive oxygen species (ROS), and apoptosis.

Key findings

• AcTor potentiates the cytotoxic activity of the proteasome inhibitor ixazomib in ex vivo primary AML patient samples.

In plain English

In vitro mechanistic assays reported that combining AcTor (a putative TSC2 inhibitor) with the proteasome inhibitor ixazomib (IXZ) produces mitochondrial dysfunction — collapse of respiratory capacity, loss of mitochondrial membrane potential, accumulation of reactive oxygen species (ROS) — accompanied by apoptosis in acute myeloid leukemia (AML) cells. These mitochondrial and apoptotic phenotypes were observed across multiple AML cell lines and primary patient samples and were reported to be enhanced in drug-resistant AML contexts.

Key findings

• Combination of AcTor and ixazomib causes collapse of mitochondrial respiratory capacity, loss of mitochondrial membrane potential, accumulation of ROS, and triggers apoptosis in AML cells.
• These mitochondrial dysfunction and apoptotic effects were observed across multiple AML cell lines and primary patient samples and were reported to be increased in drug-resistant AML models.

In plain English

From the paper abstract: AcTor (a TSC2-targeting mTOR activator) potentiates the proteasome inhibitor ixazomib (IXZ) to kill AML cells. In vitro combination treatment reduced mitochondrial respiratory capacity, collapsed mitochondrial membrane potential, increased reactive oxygen species (ROS) and induced apoptosis; the abstract reports that these mitochondrial/ cytotoxic attributes were increased in drug-resistant AML models.

Key findings

• AcTor potentiates ixazomib-induced cytotoxicity in AML in vitro; the combination causes mitochondrial respiratory collapse, loss of mitochondrial membrane potential, ROS accumulation and apoptosis — with these mitochondrial/cytotoxic attributes reported to be increased in drug-resistant AML models.

In plain English

Transcriptomic profiling reported in the abstract compared AcTor alone versus AcTor combined with ixazomib (IXZ). AcTor alone was associated with induction of anabolic and oxidative phosphorylation transcriptional programs; the AcTor+IXZ combination redirected signaling toward stress-associated and pro-apoptotic transcriptional states, including a p53 pathway signature. Methodological details (platform, sample source, replicates, and statistical thresholds) are not provided in the abstract.

Key findings

• AcTor alone induced anabolic and oxidative phosphorylation (OXPHOS) transcriptional programs.
• The combination of AcTor and ixazomib redirected signaling toward stress-associated and pro-apoptotic transcriptional states, including enrichment of a p53 pathway signature.

In plain English

The abstract reports that, in vivo, the TSC2 inhibitor AcTor combined with the proteasome inhibitor ixazomib (IXZ) reduced AML disease burden, depleted blasts and leukemic stem cells, retained anti-AML activity at relapse, and was active in a TP53‑mutant patient‑derived xenograft (PDX) model with efficacy described as exceeding standard-of-care.

Key findings

• AcTor combined with ixazomib reduced AML disease burden in in vivo models.
• The combination depleted blasts and leukemic stem cells in the reported in vivo studies.

In plain English

In vivo, the AcTor + ixazomib (IXZ) combination reduced AML burden, depleted blasts and leukemic stem cells, retained activity at relapse, and, in a TP53-mutated patient-derived xenograft (PDX) model, was reported as equally potent and to exceed the efficacy of the standard-of-care.

Key findings

• AcTor + ixazomib reduced AML burden and depleted blasts and leukemic stem cells in vivo.
• Antileukemic activity of AcTor + ixazomib was retained upon relapse in in vivo studies.